top of page
Latest Articles and Analysis
Search
PBM Reform & Drug Pricing


CVS Breaks Itself Up, and Keeps the Parts That Matter
CVS Health announced a split into two publicly traded companies, spinning off its 9,000 retail stores while keeping Aetna, Caremark, and CVS Specialty bundled together. For patients dependent on specialty drugs and 340B pricing — including people living with HIV and hepatitis C — the machinery that drives cost and steers prescriptions stays firmly intact.
Travis Roppolo
Nov 94 min read


Importation Is Not a Fix. It Is a Symptom of a System Built to Shift Cost.
Millions of Americans have bought prescription drugs from abroad not because they chose a riskier supply chain, but because payers designed coverage to move costs onto patients. The crackdown on de minimis importation is the right call on safety — but it solves nothing if the structural incentives driving patients to the border stay untouched.
Travis Roppolo
Oct 195 min read


Record Premiums, Record Profits
A 221% premium spike. Twelve million fewer Marketplace enrollees. Record insurer profits. The three converging shocks hitting American health coverage in 2026–2027 fall hardest on people living with HIV, hepatitis C, and substance use disorder — the populations for whom a coverage lapse is a treatment lapse.
Travis Roppolo
Oct 136 min read


PDABs march on, burning money, while failing to help patients.
Prescription Drug Affordability Boards have been marketed as an easy fix for drug costs — but after six years, $28 million spent, and 394 hours of meetings, not a single PDAB has delivered savings for patients or their states. The data demands accountability.
Ranier Simons and Shabbir Safdar
Aug 316 min read
We Need Your Support Today!
bottom of page